Users Coming Off Weight-Loss Jabs Gain Back Pounds Far More Rapidly Compared to Those on Conventional Diets

A recent study indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional lifestyle regimens.

Published data in a leading health publication demonstrates that while obese individuals often shed about a fifth of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"People buying these drugs should be aware of the risk of quick rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.

Such speed of recovery means a reversion to starting weight within about 18 months.

Comparing Treatments

The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with conventional dieting.

Researchers point out that individuals who shed pounds through lifestyle changes alone usually experience a less rapid weight regain—perhaps 100 grams monthly—once they finish.

Understanding the Rapid Rebound

Doctors suggest the mechanism of the injections accounts for the heightened regain.

The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Long-term administration of the hormone levels far above than the body's typical production might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making excessive eating much more probable."

An Ongoing Issue?

Health authorities advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.

A number of clinicians say that, given the significant potential of relapse, the treatment might need to be life-long.

This view is echoed by pharmaceutical companies, who state that the findings "emphasize the chronic character of excess weight," comparing it to managing conditions like hypertension.

User Accounts

Users who have come off the medication describe a powerful resurgence of appetite.

"It was like a switch flipping and I was suddenly starving," described one woman.

This difficulty is worsened if patients have not adopted sustainable dietary or behavioural modifications during therapy.

Widespread Interest

Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is higher among females than males.
• The middle-aged demographic shows the greatest level of interest.
• Many obtain the drugs through private healthcare rather than the NHS.

In conclusion, researchers caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss relies on combined lifestyle changes.